Loading clinical trials...
Loading clinical trials...
The primary objective is to describe the effectiveness of dasatinib (Sprycel®) in CML patients in China in the real-world clinical practice setting.
Bring this clarity to your next appointment.
Keep all your medical notes and next steps in one place.
Lead Sponsor
Bristol-Myers Squibb
NCT03090477 · Leukemia, Myelogenous, Chronic, BCR-ABL Positive, Medication Adherence
NCT02896842 · Leukemia, Myelogenous, Chronic, BCR-ABL Positive
NCT01768689 · Leukemia, Myelogenous, Chronic, BCR-ABL Positive, Medication Adherence
NCT01511289 · Leukemia, Leukemia, Myeloid, and more
NCT02480608 · Leukemia, Myelogenous, Chronic, BCR-ABL Positive
Local Institution
Wuhan, Hubei
Use Clareo to keep notes, questions, trial details, and next steps organized before and after appointments.
Data Source & Attribution
This clinical trial information is sourced from ClinicalTrials.gov, a service of the U.S. National Institutes of Health.
Modifications: This data has been reformatted for display purposes. Eligibility criteria have been parsed into inclusion/exclusion sections. Location data has been geocoded to enable distance-based search. For the authoritative and most current information, please visit ClinicalTrials.gov.
Neither the United States Government nor Clareo Health make any warranties regarding the data. Check ClinicalTrials.gov frequently for updates.
View ClinicalTrials.gov Terms and Conditions